Xeris Biopharma Holdings Financials - Benzinga

Xeris Biopharma Holdings Inc

XERSNASDAQ

Trade with Public

Trade with Public

$8.43

-0.01-0.12%

At close: Aug 31, 5:00 PM EST

$8.43

-0.01-0.12%

Pre-Market: 4:11 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Xeris Biopharma Holdings Financials

Xeris Biopharma Holdings (XERS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline

Benzinga Newsdesk

PRO
Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per

Benzinga Newsdesk

PRO
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.

Benzinga Newsdesk

PRO
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000M vs $383.864M Est

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.864 million estimate.

Benzinga Newsdesk

PRO
Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 116.67 percent increase over losses of $(0.06) per

Benzinga Newsdesk

Xeris Biopharma Holdings Q4 Earnings Assessment

Benzinga Insights